Manager TitleAgeSince
President - 13/12/2023
Corporate Officer/Principal 57 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 57 13/12/2023
Director/Board Member - 13/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/12/23 Issuer sale

Director

127,934 0.0678%
14/12/23 Issuer sale

Chief Executive Officer

643,595 0.3411%
14/12/23 Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.82%-2.52%+21.65%+76.86% 56.95B
+2.51%+0.75%+5.60%+37.16% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.77%-0.15%+54.99%+128.56% 43.73B
Weighted average by Cap. +1.97%-0.46%+58.92%+137.02%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock